# A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

> clinical trial · VERIFIED · 2026-08-27

Status: RECRUITING · Sponsor: Amgen · Condition: Metastatic Castration-resistant Prostate Cancer

- Company: Amgen
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07213674

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.